

# JOIN US

## in our work to advance the care for Lymphoma (Non-Hodgkin's Lymphoma)

ELiPSE-1 is open and enrolling patients with relapsed/refractory Lymphoma.

Talk to your doctor today to determine whether you or someone you know may be eligible to receive CNTY-101 through the ELiPSE-1 clinical trial.

**ELiPSE-1: A Phase 1 Study of CNTY-101, a CD19-targeted CAR-NK Cell Therapy, in Patients with Relapsed or Refractory CD19-Positive B-Cell Lymphomas (Indolent and Aggressive non-Hodgkin's lymphoma)**

ClinicalTrials.gov identifier: NCT05336409

### TRIAL OVERVIEW


ELiPSE-1 is a clinical trial to see how safe the treatment with CNTY-101 is. Another purpose is to see if the study treatment can slow the growth of your cancer. The study treatment is an investigational study treatment because it has not been approved by the US Food and Drug Administration (FDA) for use outside of a clinical study, including treatment of NHL.

CNTY-101 is a type of cell therapy because it uses immune cells to attack the cancer. CNTY-101 is not made from your own cells; it is available to treat you if you and your doctor decide it is the right treatment for you and you qualify for participation. Therapies like CNTY-101 can potentially overcome many of the challenges of current available treatment. These challenges include:


- **Patient access:** Not everyone can get current cellular treatments because sometimes the disease grows too fast or because manufacturing the treatment is difficult.
- **Treatment resistant and durability:** Not everyone who receives current cellular treatments gets better, and those who do may not stay better for long.

The duration of treatment will be a 28-day treatment cycle, consisting of a single-dose escalation of CNTY-101 intravenous (IV) infusion and subcutaneous IL-2 (Schedule A) or 3 x weekly IV infusions (Schedule B).

Century provides the following at NO COST to the patient:

 A service for booking and prepaying for hotels and transportation.

 Funds for meals for the patient and their significant other.

 Additional stipend for parking or tolls can be provided as well depending on the location and your doctor's practices. Please talk with your doctor about the trial and the help you may be able to receive.

### KEY INCLUSION CRITERIA

- Age  $\geq$  18 years
- CD19-positive relapsed or refractory (R/R) B-cell NHL
- Received multiple prior systemic therapies

### KEY EXCLUSION CRITERIA

- Central nervous system (CNS)-only involvement by malignancy (participants with secondary CNS involvement are allowed)
- Prior allogeneic stem cell transplant
- Presence of clinically significant CNS pathology


For a full list of inclusion/exclusion criteria, please visit: <https://clinicaltrials.gov/study/NCT05336409>.

For more information, please reach out to: [ClinicalTeamCNTY@centurytx.com](mailto:ClinicalTeamCNTY@centurytx.com)



[www.centurytx.com](http://www.centurytx.com)

# What to Expect in the ELIPSE-1 Clinical Trial



## FREQUENTLY ASKED QUESTIONS

### What are clinical trials?

Clinical trials are research studies that test a new therapeutic in humans with the goal of finding better ways to prevent, diagnose or treat disease. A Phase I clinical trial determines if a treatment is safe and well tolerated.

### What are B-cell lymphomas?

B-cell lymphomas are a group of cancers that originate from B-cells. B-cells play an important role in the immune system by producing antibodies to fight off infections and disease.

B-cell lymphomas make up most of the non-Hodgkin's lymphoma (NHL) cases.

### What is non-Hodgkin's lymphoma (NHL)?

NHL is a type of cancer that typically affects the lymphatic system, which is a part of the body's immune system. In NHL, abnormal B-cells grow uncontrollably, leading to tumors forming in lymph nodes or other lymphatic tissues found in organs.

### What are CD19-targeted therapies?

CNTY-101 is a CAR-NK cell therapy targeting CD19. CD19 is a protein found only on B-cells. It's present in most B-cell lymphomas but not in other types of cells. Therefore, CD19 may be a good target for therapies that aim to remove B-cells from the body.

CNTY-101 is designed to:

- Specifically recognize and target CD19-expressing B-cells.
- Improve functionality and persistence of cells for potentially deeper and more durable responses via repeat dosing.
- Provide the option to eliminate the drug product if ever necessary.